OncoMatch/Clinical Trials/NCT07665515
Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Is NCT07665515 recruiting? Yes, currently enrolling (Jul 2026). This Phase 1 trial studies CryptiVax-1001 for ovarian cancer.
Treatment: CryptiVax-1001 — Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer. The most common and aggressive form is called high-grade serous ovarian cancer. The main purpose of this study is to understand whether an experimental study vaccine, CryptiVax-1001, is safe when administered to patients with high-grade serous ovarian cancer (HGSOC). The study vaccine is a cancer vaccine, which aims to delay or possibly prevent the cancer from coming back. However, as this is the first study of the vaccine in patients, the primary purpose of this study is to assess the safety of the study vaccine. Following surgery and platinum-based chemotherapy participants may enter the trial and receive CryptiVax-1001 as an explorative maintenance therapy. The main purposes of this study are therefore to: * assess how well the study vaccine is tolerated and identify any side effects. * analyse the study vaccine's capacity to activate your immune system The study will test escalating dose levels of CryptiVax-1001 based on the safety evaluations to estimate appropriate future dose levels for CryptiVax-1001.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 wild-type
Required: BRCA2 wild-type
Disease stage
Required: Stage FIGO 2014 STAGE III, FIGO 2014 STAGE IV (other)
Grade: high-grade
The FIGO 2014 stage III or IV disease at initial diagnosis
Performance status
ECOG 0–1(Restricted strenuous activity)
ECOG performance status of 0 or 1
Demographics
Prior therapy
Must have received: platinum-based chemotherapy (carboplatin, paclitaxel) — first-line (neoadjuvant or adjuvant, or both)
Completed first-line platinum-based chemotherapy (minimum 4 cycles of carboplatin and paclitaxel, or equivalent, received in either neoadjuvant or adjuvant, or both settings)
Cannot have received: bevacizumab in first-line maintenance (bevacizumab)
No prior, current, or planned treatment with bevacizumab or PARPi in the first-line maintenance setting
Cannot have received: PARP inhibitor in first-line maintenance
No prior, current, or planned treatment with bevacizumab or PARPi in the first-line maintenance setting
Cannot have received: cancer vaccine
Previous treatment with any cancer vaccine
Cannot have received: checkpoint inhibitor
Previous treatment with any...checkpoint inhibitor
Cannot have received: adoptive cellular immunotherapy
Previous treatment with any...adoptive cellular immunotherapy
Lab requirements
Blood counts
Kidney function
Liver function
Adequate haematologic and organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07665515 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior bevacizumab in first-line maintenance, PARP inhibitor in first-line maintenance, cancer vaccine disqualifies patients from enrollment.
Does this trial require BRCA1?
Yes, BRCA1 wild-type is a required biomarker for enrollment.
Does this trial require BRCA2?
Yes, BRCA2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage FIGO 2014 STAGE III or FIGO 2014 STAGE IV is required.
Is this trial open to male patients?
No. This trial enrolls female patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages